Mallinckrodt Plc is finalizing a settlement proposal of at least $1.6 billion that would place its U.S. generic drug business into bankruptcy to address the debt maturities and liabilities arising out of the opioid crisis, the Wall Street Journal reported on Monday.
Source:: Reuters – Business News
